Published in Cancer Weekly, December 24th, 2002
According to N. Leone and coworkers at Molinette Hospital in Turin, Italy, serum chromogranin A levels rise in patients with epithelioid tumors that differentiate. High levels of the marker predict worse outcomes. The investigators now believe chromogranin A levels also rise in patients with HCC, signaling neuroendocrine differentiation in those tumors as well.
Leone and colleagues analyzed chromogranin A levels in 79 patients with diagnoses of HCC and cirrhosis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.